Mettler-Toledo International, INYSE: MTD
Health Care · Life Sciences Tools & Services
$1,269.64
-0.55%
Vol: 67K
Research Digest
Friday, May 1, 2026
Mettler Toledo Q4 2025 sales up 8%; Q1 2026 earnings due May 7
Mettler-Toledo reported Q4 2025 results with sales up 8% YoY ($1.5B local currency increase of 5%), and adjusted EPS up 8% to $13.36. Company appointed Michael Tokich and Pablo Perversi to Board. Q1 2026 earnings due May 7 after market close with earnings call May 8. Barclays and Evercore ISI both lowered price targets in April 2026. Trading at $1,264.36 with average 12-month PT of $1,488.31 and Buy consensus from analysts.
Previous Market Intelligence
13 daysApr 30Mettler Toledo launches M50 R-Series metal detectors April 27 and reinforces Eagle integration; stock down 3.5% on April 23 amid analyst downgrades.Neutral▶
Mettler-Toledo announced the launch of M50 R-Series AdvancedLine metal detectors on April 27 designed to adapt to evolving operational and regulatory requirements. On April 28, the company announced closer alignment of Eagle Product Inspection with global operations. Mettler-Toledo will showcase product inspection innovations at Interpack 2026 (May 7-13) in Dusseldorf, including the first European presentation of the X3 Bulk Series and Eagle MAXIMIZER RMI. Stock fell 3.5% on April 23 to $1,264.36. Analyst price targets were lowered: Barclays cut to $1,500 from $1,550 on April 14, and Evercore ISI lowered to $1,425 from $1,515 on April 6. YTD the stock is down 5.0%.
Apr 29No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 16Mettler-Toledo reports Q3 2025 sales up 8% YoY to $1,029.7M with adjusted EPS of $11.15, up 9% annually.Positive▶
Mettler-Toledo International reported Q3 2025 results with sales of $1,029.7 million, representing 8% year-over-year growth and 6% local currency growth. Adjusted diluted EPS rose to $11.15, up 9% compared to the prior-year period, while GAAP diluted EPS reached $10.57 versus $9.96 a year earlier. The company, a global supplier of precision instruments and services for life sciences, food, chemicals, and industrial applications, also announced Michael J. Tokich joining the Board of Directors. Morgan Stanley lowered its price target to $1,475 from $1,550 in February. The average analyst rating is Buy with a 12-month price target of $1,446.25, suggesting 15.89% upside potential.
Apr 15Mettler-Toledo schedules Q1 2026 earnings May 7; stock down 11% YTD but maintains Moderate Buy consensus.Neutral▶
Mettler-Toledo International will release Q1 2026 results May 7 after-hours. Stock trading at $1,415.82, with YTD decline of 11% but +23.2% over past 12 months. Institutional activity mixed: Sumitomo Mitsui Trust reduced stake 4.8%, Robeco lowered position 3.9%. Consensus rating Moderate Buy with PT of $1,463.75. No material overnight news; focus on upcoming earnings.
Apr 14Mettler-Toledo reports strong Q4 2025 EPS beat at $13.36; Q1 2026 results due May 7 with consensus price target $1,463.75.Positive▶
Mettler-Toledo beat Q4 2025 expectations with EPS of $13.36 (vs. consensus $12.76) and revenue of $1.13 billion. Company provided 2026 adjusted EPS guidance of $46.38 at midpoint. Q1 results May 7. Consensus analyst rating Moderate Buy with average target $1,463.75. Year-to-date down 11%.
Apr 13Mettler-Toledo Q1 2026 earnings May 7 after-market; analyst ratings conflicted amid tariff/shipping headwinds.Neutral▶
Mettler-Toledo reported Q3 2025 sales $1,029.7M (+8% YoY), GAAP EPS $10.57 vs $9.96, Adjusted EPS $11.15 (+9%). Board authorized $2.75B share repurchase. Management guided reflecting tariff/shipping delays. Q1 2026 earnings due May 7 after-market. Michael J. Tokich appointed to Board (Feb 2026). Morgan Stanley lowered PT to $1,475; BofA raised to $1,640.
Apr 10Mettler-Toledo Reports Q4 2025 Beat on Strong Adjusted EPS GrowthNeutral▶
Q4 adjusted EPS of $13.36 (+8% YoY). Jefferies raised target to $1,450. Morgan Stanley set target at $1,475.
Apr 9Mettler Toledo Reports 8% Sales Growth in Q4 2025 With Strong Board AdditionsPositive▶
Mettler-Toledo International reported Q4 2025 sales increased 8% (5% in local currency) with reported net earnings per diluted share of $13.98 (vs. $11.96 prior year) and adjusted EPS of $13.36 (up 8%). The company holds global number-one market positions across most businesses in life sciences, food, and chemicals. Michael J. Tokich was appointed to the Board effective February 5, 2026. Twelve analysts rate the stock "Buy" with an average 12-month price target of $1,446.25, representing 15.89% upside.
Apr 8Morgan Stanley lowers Mettler-Toledo target to $1,475 amid valuation concerns.Negative▶
Morgan Stanley lowered MTD PT to $1,475 from $1,550 February 10. UBS Neutral. Michael Tokich appointed to Board. Stock touched 52-week low $1,141.79.
Apr 7Mettler-Toledo Reports Strong Q4; Analyst Maintains Outperform RatingPositive▶
Q4 2025 results beat with reported sales +8% YoY (5% local currency) and Adjusted EPS +8% to $13.36. Evercore ISI maintained Outperform rating with price target at $1,425. Pharmaceutical and biopharma facility expansion tailwinds support long-term growth outlook.
Apr 6Mettler-Toledo hits 52-week low; UBS maintains Neutral amid tariff headwinds and guidance cuts.Negative▶
Mettler-Toledo International touched 52-week low at $1,141.79, trading at $1,165.17 (down 1.01% to -11.93). UBS maintained Neutral rating on Friday. Company faces headwinds from global trade disputes, estimated incremental tariff costs of $115M annually. Q1 2025 results mixed: reported sales down 5% to $883.7M. Management revised 2025 guidance downward to 1-2% local currency sales growth, Adjusted EPS $41.25-$42.00. Michael J. Tokich appointed to Board effective Feb 5, 2026. Morgan Stanley previously cut price target to $1,475 from $1,550 on Feb 10. Buy consensus from 12 analysts, $1,446.25 target (15.89% upside).
Apr 3Mettler-Toledo showcases pharma inspection tech at Interphex 2026; Q4 beat and raised FY2026 guidance; earnings April 30.Positive▶
Mettler-Toledo will exhibit at Interphex 2026 (April 21-23) with strong momentum from Q4 2025 results. The company beat estimates with Q4 sales of $1,129.7M and raised full-year 2026 EPS guidance by $0.70. Targets $900M free cash flow and $825M-$875M in share repurchases for 2026. Earnings date April 30.
Apr 2No significant overnight updatesNeutral▶
No material news in the last 48 hours. Most recent developments include board appointment of Michael J. Tokich (former STERIS CFO) effective February 5, 2026, and Q4 2025 earnings with sales of $1.13 billion beating consensus. Company guides for 4% constant currency revenue growth in 2026 with consensus EPS estimates projecting $46.49, an 8.8% gain.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $469.56 | -1.96% | -1.9% | 17.5x | 0.97 | $178.0B |
| DHRDANAHER | $175.47 | -1.95% | -6.9% | 19.7x | 0.99 | $126.7B |
| AAGILENT | $114.69 | -0.74% | +0.6% | 17.6x | 1.30 | $32.7B |
| WATWATERS | $306.56 | -0.86% | +1.7% | 18.9x | 1.20 | $30.4B |
| IQVIQVIA | $157.04 | -0.84% | -7.2% | 11.3x | 1.39 | $26.6B |
| MTDMETTLER | $1,269.64 | -0.55% | +0.8% | 24.9x | 1.44 | $25.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.